Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity.
Accession Therapeutics has raised $31.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2024.
Accession Therapeutics's investors include Primavera Capital Group, iGlobe Partners, Birk Venture.
Accession Therapeutics is headquartered in Oxford, United Kingdom.
Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity.
Accession Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Accession Therapeutics — Funding & Investors." VCBacked, April 25, 2024, https://www.vcbacked.co/company/accession-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). Accession Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/accession-therapeutics
{{cite web |title=Accession Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/accession-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated